Zydus Lifesciences gets USFDA’s approval for Pemetrexed for Injection

26 May 2022 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Pemetrexed for Injection, in the strengths of 100 mg/vial, 500 mg/vial, and 1000 mg/vial Single-Dose Vials.

Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. The drug will be manufactured at Zydus Hospira. Pemetrexed for Injection has a market size of $1,236 million (as per IQVIA MAT March’22).

The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

888.00 -5.45 (-0.61%)
28-Jan-2026 10:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1616.75
Dr. Reddys Lab 1226.10
Cipla 1319.25
Zydus Lifesciences 888.00
Lupin 2125.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×